Scleritis Market Research Report - Forecast till 2027

Scleritis Market Research Report: Information by Type (Anterior and Posterior), Diagnostic Test & Treatment (Ultrasonography, Prednisolone, Ibuprofen, Methotrexate and Mycophenolate), End User (Hospitals & Clinics, Diagnostic Centres) - Forecast till 2027

ID: MRFR/Pharma/1224-HCR | August 2022 | Region: Global | 90 Pages         

Table of Contents:

Chapter 1. Executive Summary

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Overview

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.2.1 R&D and Designing

5.2.2 Manufacturing

5.2.3 Distribution & Sales

5.2.4 Post-Sales Review

Chapter 6. Global Scleritis Market, by Type

6.1 Overview

6.2 Anterior Scleritis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.1 Diffuse Scleritis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.2 Nodular Scleritis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.2.3 Necrotizing Scleritis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3 Posterior Scleritis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

 

Chapter 7. Global Scleritis Market, by Diagnostic Test & Treatment

7.1 Overview

7.2 Diagnostic Test

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.1 Ultrasonography

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.2 Complete Blood Count

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.3 Biopsy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.4 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3 Treatment

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3.1 Medication

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3.1.1 Corticosteroid

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3.1.1.1 Difluprednate

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3.1.1.2 Prednisolone

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3.1.1.3 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3.1.2 Nonsteroidal Anti-Inflammatory Drugs

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3.1.2.1 Aspirin

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3.1.2.2 Ibuprofen

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3.1.2.3 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3.1.3 Immunosuppressive Drugs

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3.1.3.1 Methotrexate

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3.1.3.2 Mycophenolate

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3.1.3.3 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

 

Chapter 8. Global Scleritis Market, by End User

8.1 Overview

8.2 Hospitals & Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3 Diagnostic Centers

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4 Academic & Research Organizations

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 10. Global Scleritis Market, by Region

10.1 Overview

10.2 Americas

10.2.1 North America

10.2.1.1 US

10.2.1.2 Canada

10.2.2 Latin America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 UK

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia-Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 South Korea

10.4.6 Rest of Asia-Pacific

10.5 Middle East & Africa

10.5.1 Middle East

10.5.2 Africa

Chapter 11. Company Landscape

11.1 Overview

11.2 Competitive Analysis

Chapter 12. Company Profile

12.1 Amgen

12.1.1 Company Overview

12.1.2 Products/Services Offered

12.1.3 Financial Overview

12.1.4 Key Developments

12.1.5 SWOT Analysis

12.1.6 Key Strategies

12.2 Amneal Pharmaceuticals LLC

12.2.1 Company Overview

12.2.2 Products/Services Offered

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.2.6 Key Strategies

12.3 Baxter International Inc.

12.3.1 Company Overview

12.3.2 Products/Services Offered

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.3.6 Key Strategies

12.4 Boehringer Ingelheim

12.4.1 Company Overview

12.4.2 Products/Services Offered

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.4.6 Key Strategies

12.5 Fresenius Kabi USA, LLC

12.5.1 Company Overview

12.5.2 Products/Services Offered

12.5.3 Financial overview

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.5.6 Key Strategies

12.6 Jubilant Pharmaceuticals Inc.

12.6.1 Company Overview

12.6.2 Products/Services Offered

12.6.3 Financial Overview

12.6.4 Key Developments

12.6.5 SWOT Analysis

12.6.6 Key Strategies

12.7 Mylan Pharmaceuticals Inc.

12.7.1 Overview

12.7.2 Products/Services Offered

12.7.3 Financial Overview

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.7.6 Key Strategies

12.8 Novartis Pharmaceuticals

12.8.1 Overview

12.8.2 Products/Services Offered

12.8.3 Financial Overview

12.8.4 Key Developments

12.8.5 SWOT Analysis

12.8.6 Key Strategies

12.9 Perrigo Company

12.9.1 Overview

12.9.2 Products/Services Offered

12.9.3 Financial Overview

12.9.4 Key Developments

12.9.5 SWOT Analysis

12.9.6 Key Strategies

12.10 Sandoz Inc.

12.10.1 Overview

12.10.2 Products/Services Offered

12.10.3 Financial Overview

12.10.4 Key Developments

12.10.5 SWOT Analysis

12.10.6 Key Strategies

12.11 Shanghai Henlius Biotech

12.11.1 Overview

12.11.2 Products/Services Offered

12.11.3 Financial Overview

12.11.4 Key Developments

12.11.5 SWOT Analysis

12.11.6 Key Strategies

12.12 Teva Pharmaceuticals USA, Inc.

12.10.1 Overview

12.10.2 Products/Services Offered

12.10.3 Financial Overview

12.10.4 Key Developments

12.10.5 SWOT Analysis

12.10.6 Key Strategies

12.13 West-Ward Pharmaceuticals

12.13.1 Overview

12.13.2 Products/Services Offered

12.13.3 Financial Overview

12.13.4 Key Developments

12.13.5 SWOT Analysis

12.13.6 Key Strategies

12.14 Zydus Pharmaceuticals (USA) Inc.

12.14.1 Overview

12.14.2 Products/Services Offered

12.14.3 Financial Overview

12.14.4 Key Developments

12.14.5 SWOT Analysis

12.14.6 Key Strategies

12.15 Roxane Laboratories, Inc.

12.15.1 Overview

12.15.2 Products/Services Offered

12.15.3 Financial Overview

12.15.4 Key Developments

12.15.5 SWOT Analysis

12.15.6 Key Strategies

12.16 Others

Chapter 13 Appendix

13.1 References

13.2 Related Reports

 

LIST OF TABLES

Table 1 Global Scleritis Market Synopsis, 2020-2027

Table 2 Global Scleritis Market Estimates and Forecast, 2020-2027 (USD Million)

Table 3 Global Scleritis Market, by Type, 2020-2027 (USD Million)

Table 4 Global Scleritis Market, by Diagnostic Test & Treatment, 2020-2027 (USD Million)

Table 5 Global Scleritis Market, by End User, 2020-2027 (USD Million)

Table 6 Global Scleritis Market, by Region, 2020-2027 (USD Million)

Table 7 Americas: Scleritis Market, by Region, 2020 and 2025

Table 8 Americas: Scleritis Market, by Type, 2020-2027 (USD Million)

Table 9 Americas: Scleritis Market, by Diagnostic Test & Treatment, 2020-2027 (USD Million)

Table 10 Americas Scleritis Market, by End User, 2020-2027 (USD Million)

Table 11 North America: Scleritis Market, by Country, 2020-2027 (USD Million)

Table 12 North America: Scleritis Market, by Type, 2020-2027 (USD Million)

Table 13 North America: Scleritis Market, by Diagnostic Test & Treatment, 2020-2027 (USD Million)

Table 14 North Americas Scleritis Market, by End User, 2020-2027 (USD Million)

Table 15 US: Scleritis Market, by Type, 2020-2027 (USD Million)

Table 16 US: Scleritis Market, by Diagnostic Test & Treatment, 2020-2027 (USD Million)

Table 17 US: Scleritis Market, by End User, 2020-2027 (USD Million)

Table 18 Canada: Scleritis Market, by Type, 2020-2027 (USD Million)

Table 19 Canada: Scleritis Market, by Diagnostic Test & Treatment, 2020-2027 (USD Million)

Table 20 Canada: Scleritis Market, by End User, 2020-2027 (USD Million)

Table 21 Latin America: Scleritis Market, by Type, 2020-2027 (USD Million)

Table 22 Latin America: Scleritis Market, by Diagnostic Test & Treatment, 2020-2027 (USD Million)

Table 23 Latin America: Scleritis Market, by End User, 2020-2027 (USD Million)

Table 24 Europe: Scleritis Market, by Region, 2020-2027 (USD Million)

Table 25 Europe: Scleritis Market, by Type, 2020-2027 (USD Million)

Table 26 Europe: Scleritis Market, by Diagnostic Test & Treatment, 2020-2027 (USD Million)

Table 27 Europe: Scleritis Market, by End User, 2020-2027 (USD Million)

Table 28 Western Europe: Scleritis Market, by Country, 2020-2027 (USD Million)

Table 29 Western Europe: Scleritis Market, by Type, 2020-2027 (USD Million)

Table 30 Western Europe: Scleritis Market, by Diagnostic Test & Treatment, 2020-2027 (USD Million)

Table 31 Western Europe: Scleritis Market, by End User, 2020-2027 (USD Million)

Table 32 Eastern Europe: Scleritis Market, by Type, 2020-2027 (USD Million)

Table 33 Eastern Europe: Scleritis Market, by Diagnostic Test & Treatment, 2020-2027 (USD Million)

Table 34 Eastern Europe: Scleritis Market, by End User, 2020-2027 (USD Million)

Table 35 Asia-Pacific: Scleritis Market, by Country, 2020-2027 (USD Million)

Table 36 Asia-Pacific: Scleritis Market, by Type, 2020-2027 (USD Million)

Table 37 Asia-Pacific: Scleritis Market, by Diagnostic Test & Treatment, 2020-2027 (USD Million)

Table 38 Asia-Pacific: Scleritis Market, by End User, 2020-2027 (USD Million)

Table 39 Middle East & Africa: Scleritis Market, by Region, 2020-2027 (USD Million)

Table 40 Middle East & Africa: Scleritis Market, by Type, 2020-2027 (USD Million)

Table 41 Middle East & Africa: Scleritis Market, by Diagnostic Test & Treatment, 2020-2027 (USD Million)

Table 42 Middle East & Africa: Scleritis Market, by End User, 2020-2027 (USD Million)

 

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Market Structure of the Global Scleritis Market

Figure 3 Market Dynamics of the Global Scleritis Market

Figure 4 Global Scleritis Market Share, by Type, 2020 (%)

Figure 5 Global Scleritis Market Share, by Type, 2020 (USD Million)

Figure 6 Global Scleritis Market Share, by Diagnostic Test & Treatment, 2020 (%)

Figure 7 Global Scleritis Market Share, by Diagnostic Test & Treatment, 2020 (USD Million)

Figure 8 Global Scleritis Market Share, by End User, 2020 (%)

Figure 9 Global Scleritis Market Share, by End User, 2020 (USD Million)

Figure 10 Global Scleritis Market Share, by Region, 2020 (%)

Figure 11 Americas: Scleritis Market Share, by Region, 2020 (%)

Figure 12 North America: Scleritis Market Share, by Country, 2020 (%)

Figure 13 Europe: Scleritis Market Share, by Region, 2020 (%)

Figure 14 Asia-Pacific: Scleritis Market Share, by Country, 2020 (%)

Figure 15 Middle East & Africa: Scleritis Market Share, by Region, 2020 (%)

Figure 16 Global Scleritis Market: Company Share Analysis, 2020 (%)

Figure 17 Amgen: Key Financials

Figure 18 Amgen: Segmental Revenue

Figure 19 Amgen: Regional Revenue

Figure 20 Amneal Pharmaceuticals LLC: Key Financials

Figure 21 Amneal Pharmaceuticals LLC: Segmental Revenue

Figure 22 Amneal Pharmaceuticals LLC: Regional Revenue

Figure 23 Baxter International Inc.: Key Financials

Figure 24 Baxter International Inc.: Segmental Revenue

Figure 25 Baxter International Inc.: Regional Revenue

Figure 26 Boehringer Ingelheim: Key Financials

Figure 27 Boehringer Ingelheim: Segmental Revenue

Figure 28 Boehringer Ingelheim: Regional Revenue

Figure 29 Fresenius Kabi USA, LLC: Key Financials

Figure 30 Fresenius Kabi USA, LLC: Segmental Revenue

Figure 31 Fresenius Kabi USA, LLC: Regional Revenue

Figure 32 Mylan Pharmaceuticals Inc.: Key Financials

Figure 33 Mylan Pharmaceuticals Inc.: Segmental Revenue

Figure 34 Mylan Pharmaceuticals Inc.: Regional Revenue

Figure 35 Novartis Pharmaceuticals: Key Financials

Figure 36 Novartis Pharmaceuticals: Segmental Revenue

Figure 37 Novartis Pharmaceuticals: Regional Revenue

Figure 38 Perrigo Company: Key Financials

Figure 39 Perrigo Company: Segmental Revenue

Figure 40 Perrigo Company: Regional Revenue

Figure 41 Sandoz Inc.: Key Financials

Figure 42 Sandoz Inc.: Segmental Revenue

Figure 43 Sandoz Inc.: Regional Revenue

Scleritis Market Speak to Analyst Request a Free Sample

Scleritis Market Scenario


Scleritis is a medical condition that causes painful inflammation of sclera (white part of the eye). In some severe cases, the disease is reported to cause loss of vision, i.e., by affecting episclera and sclera. Thus, its timely diagnosis and treatment are necessary against scleritis. Focal redness or violaceous discoloration, scleral thickening, late scleral, and scleral necrosis are some of the prominent symptoms associated with the disease.


It is established that more than 50% of scleritis cases are associated with autoimmune disease, including rheumatoid arthritis. The prevalence of rheumatoid arthritis is increasing and, thus, the susceptible scleritis patient population. It is suggestive that the prevalence of rheumatoid arthritis was about 0.5–1.0% within regional boundaries of North America and Northern Europe. This scleritis market is indicating a positive market growth during the forecast period, 2018–2025.


Moreover, factors such as the growing aging population and increasing per capita healthcare expenditure boost the market growth. However, lack of awareness in the middle-income countries and the absence of targeted treatment is estimated to restraint the market growth during the forecast period.


Scleritis Market is expected to grow with a healthy CAGR of approximately 6.0% during the forecast period.


Segmentation


scleritis market has been segmented into type, diagnostic test & treatment, end-user, and region.


The scleritis market, based on type, has been segmented into anterior scleritis and posterior scleritis. The anterior scleritis segment is further segmented into diffuse scleritis, nodular scleritis, and necrotizing scleritis.


The scleritis global market, by diagnostic test & treatment, has been divided into diagnostic tests and treatment. The diagnostic test market is further segmented into ultrasonography, complete blood count, biopsy, others.


The treatment segment is sub-divided into medication and surgery. The medication segment is further classified into corticosteroid, nonsteroidal anti-inflammatory drugs, and immunosuppressive drugs. The corticosteroid segment is sub-segmented into difluprednate, prednisolone, and others. The nonsteroidal anti-inflammatory drugs segment is further classified into aspirin, ibuprofen, and others. The immunosuppressive drugs segment is sub-segmented into methotrexate, mycophenolate, and others.


The end-user segment has been segmented into hospitals & clinics, diagnostic centers, and academic & research organizations.


Key Players


Amgen, Amneal Pharmaceuticals LLC, Baxter International Inc., Boehringer Ingelheim, Fresenius Kabi USA, LLC, Jubilant Cadista Pharmaceuticals Inc., Mylan Pharmaceuticals Inc., Novartis Pharmaceuticals, Perrigo Company, Roxane Laboratories, Inc., Sandoz Inc., Shanghai Henlius Biotech, Teva Pharmaceuticals USA, Inc., West-Ward Pharmaceuticals, Zydus Pharmaceuticals (USA) Inc. are some of the key players operating in the scleritis market.  


Regional Market Summary


Scleritis Global Market Share (%), by Region, 2018


Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, Annual Reports


Geographically, the Americas is projected to lead the scleritis market. This can be attributed due to the presence of well-developed healthcare infrastructure and the increasing prevalence of scleritis within the Americas.


Europe is expected to hold the second-largest share of the scleritis market owing to government support and the presence of developed countries such as the UK, Germany, and France within the region.


The scleritis market in Asia-Pacific is segmented into China, Japan, India, Australia, South Korea, and the rest of the Asia-Pacific. The region is estimated to grow with the highest CAGR. High prevalence of scleritis, growing geriatric population, and increasing penetration of market players boost the regional market. In India, the mean age of scleritis patients is estimated to be about 55. This susceptible age group is expanding, which is growing the treatment-seeking patient pool.


The Middle East & Africa is anticipated to hold the least share of the market owing to the presence of poor economies, stringent government regulations, and low per capita income in Africa. Within the region, the Middle East is projected to lead the market owing to developed healthcare infrastructure and the presence of economies such as Saudi Arabia, Kuwait, and Dubai.


Scleritis Market, by Type



  • Anterior Scleritis

    • Diffuse Scleritis

    • Nodular Scleritis

    • Necrotizing Scleritis



  • Posterior Scleritis


Scleritis Market, by Diagnostic Test & Treatment



  • Diagnostic Test

    • Ultrasonography

    • Complete Blood Count

    • Biopsy

    • Others



  • Treatment

    • Medication

      • Corticosteroid

        • Difluprednate

        • Prednisolone

        • Others



      • Nonsteroidal Anti-Inflammatory Drugs

        • Aspirin

        • Ibuprofen

        • Others



      • Immunosuppressive Drugs

        • Methotrexate

        • Mycophenolate

        • Others





    • Surgery




Scleritis Market, by End User



  • Hospitals & Clinics

  • Diagnostic Centers

  • Academic & Research Organizations


Scleritis Market, by Region



  • Americas

    • North America

    • US

    • Canada

    • South America





  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe





  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific 





  • Middle East & Africa

    • Middle East

    • Africa




Intended Audience

  • Pharmaceutical companies

  • Medical devices companies

  • Contract research organizations

  • Contract manufacturing organizations

  • Research and development organization

  • Academics and research institutes



Report Scope:
Report Attribute/Metric Details
  Market Size   2025: Significant Value
  CAGR   6.0% (2019-2025)
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Amgen, Amneal Pharmaceuticals LLC, Baxter International Inc., Boehringer Ingelheim, Fresenius Kabi USA, LLC, Jubilant Cadista Pharmaceuticals Inc., Mylan Pharmaceuticals Inc., Novartis Pharmaceuticals, Perrigo Company, Roxane Laboratories, Inc., Sandoz Inc., Shanghai Henlius Biotech, Teva Pharmaceuticals USA, Inc., West-Ward Pharmaceuticals, Zydus Pharmaceuticals (USA)
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Rising per capita healthcare expenditure.
  • growing aging population


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Sceleritis are of two types- anterior and posterior.

    Sceleristis market is predicted to grow at a 6.0% CAGR during 2018-2025.

    The key end users of the scleritis market include academic and research organizations, diagnostic centres, and hospitals and clinics.

    Rising per capita healthcare expenditure and growing aging population are the key factors driving the sceleritis market growth.

    Key players profiled in the scleritis market include Zydus Pharmaceuticals (USA) Inc., West-Ward Pharmaceuticals, Teva Pharmaceuticals USA, Inc., Shanghai Henlius Biotech, Sandoz Inc., Roxane Laboratories, Inc., Perrigo Company, Novartis Pharmaceuticals, Mylan Pharmaceuticals Inc., Jubilant Cadista Pharmaceuticals Inc., Fresenius Kabi USA, LLC, Boehringer Ingelheim, Baxter International Inc., Amneal Pharmaceuticals LLC, and Amgen.